152 related articles for article (PubMed ID: 25139687)
41. Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
Delwail V; Jais JP; Colonna P; Andrieu JM
Br J Haematol; 2002 Jul; 118(1):189-94. PubMed ID: 12100147
[TBL] [Abstract][Full Text] [Related]
42. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
43. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
[TBL] [Abstract][Full Text] [Related]
44. Is BEACOPP better than ABVD?
Cheson BD
Curr Hematol Malig Rep; 2007 Jul; 2(3):161-6. PubMed ID: 20425365
[TBL] [Abstract][Full Text] [Related]
45. ABVD vs BEACOPP escalated in advanced-stage Hodgkin's lymphoma: Results from a multicenter European study.
Mondello P; Musolino C; Dogliotti I; Bohn JP; Cavallo F; Ferrero S; Botto B; Cerchione C; Nappi D; De Lorenzo S; Martinelli G; Wolf D; Schmitt C; Loseto G; Cuzzocrea S; Willenbacher W; Mian M; Straus DJ
Am J Hematol; 2020 Sep; 95(9):1030-1037. PubMed ID: 32419224
[TBL] [Abstract][Full Text] [Related]
46. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519).
Johnson PW; Radford JA; Cullen MH; Sydes MR; Walewski J; Jack AS; MacLennan KA; Stenning SP; Clawson S; Smith P; Ryder D; Hancock BW;
J Clin Oncol; 2005 Dec; 23(36):9208-18. PubMed ID: 16314615
[TBL] [Abstract][Full Text] [Related]
47. Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.
Tesch H; Diehl V; Lathan B; Hasenclever D; Sieber M; Rüffer U; Engert A; Franklin J; Pfreundschuh M; Schalk KP; Schwieder G; Wulf G; Dölken G; Worst P; Koch P; Schmitz N; Bruntsch U; Tirier C; Müller U; Loeffler M
Blood; 1998 Dec; 92(12):4560-7. PubMed ID: 9845521
[TBL] [Abstract][Full Text] [Related]
48. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease.
Schlembach PJ; Wilder RB; Jones D; Ha CS; Fayad LE; Younes A; Hagemeister F; Hess M; Cabanillas F; Cox JD
Cancer J; 2002; 8(5):377-83. PubMed ID: 12416895
[TBL] [Abstract][Full Text] [Related]
49. ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease.
Zinzani PL; Magagnoli M; Frezza G; Barbieri E; Gherlinzoni F; Galuppi A; Bendandi M; Merla E; Albertini P; Babini L; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):553-9. PubMed ID: 10048428
[TBL] [Abstract][Full Text] [Related]
50. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group.
Diehl V; Franklin J; Hasenclever D; Tesch H; Pfreundschuh M; Lathan B; Paulus U; Sieber M; Rueffer JU; Sextro M; Engert A; Wolf J; Hermann R; Holmer L; Stappert-Jahn U; Winnerlein-Trump E; Wulf G; Krause S; Glunz A; von Kalle K; Bischoff H; Haedicke C; Duehmke E; Georgii A; Loeffler M
J Clin Oncol; 1998 Dec; 16(12):3810-21. PubMed ID: 9850026
[TBL] [Abstract][Full Text] [Related]
51. A randomized trial of brief treatment of early- stage Hodgkin lymphoma: Is it effective?
Hamed RH; Anter AH; Awad IA
Hematol Oncol Stem Cell Ther; 2012; 5(1):36-41. PubMed ID: 22446609
[TBL] [Abstract][Full Text] [Related]
52. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
[TBL] [Abstract][Full Text] [Related]
53. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. German Hodgkins' Study Group (GHSG).
Diehl V; Loeffler M; Pfreundschuh M; Ruehl U; Hasenclever D; Nisters-Backes H; Sieber M; Smith K; Tesch H; Geilen W
Ann Oncol; 1995 Nov; 6(9):901-10. PubMed ID: 8624293
[TBL] [Abstract][Full Text] [Related]
54. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
Fuchs M; Goergen H; Kobe C; Kuhnert G; Lohri A; Greil R; Sasse S; Topp MS; Schäfer E; Hertenstein B; Soekler M; Vogelhuber M; Zijlstra JM; Keller UB; Krause SW; Wilhelm M; Maschmeyer G; Thiemer J; Dührsen U; Meissner J; Viardot A; Eich H; Baues C; Diehl V; Rosenwald A; von Tresckow B; Dietlein M; Borchmann P; Engert A
J Clin Oncol; 2019 Nov; 37(31):2835-2845. PubMed ID: 31498753
[TBL] [Abstract][Full Text] [Related]
55. Standard therapy of advanced Hodgkin lymphoma.
Kuruvilla J
Hematology Am Soc Hematol Educ Program; 2009; ():497-506. PubMed ID: 20008235
[TBL] [Abstract][Full Text] [Related]
56. Intermediate stage Hodgkin's disease: preliminary results on 210 patients treated with four ABVD chemotherapy cycles plus extended versus involved field radiotherapy.
Anselmo AP; Cavalieri E; Osti FM; Cantonetti M; De Sanctis V; Alfo M; Amadori S; Enrici RM
Anticancer Res; 2004; 24(6):4045-50. PubMed ID: 15736450
[TBL] [Abstract][Full Text] [Related]
57. Communication challenges in a young man with Hodgkin's disease.
Medoff E
Cancer Pract; 2001; 9(6):272-6. PubMed ID: 11879328
[No Abstract] [Full Text] [Related]
58. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
59. Fertility in young patients following treatment for Hodgkin's lymphoma: a single center survey.
Boltežar L; Pintarić K; Jezeršek Novaković B
J Assist Reprod Genet; 2016 Mar; 33(3):325-333. PubMed ID: 26678493
[TBL] [Abstract][Full Text] [Related]
60. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era.
Montoto S; Shaw K; Okosun J; Gandhi S; Fields P; Wilson A; Shanyinde M; Cwynarski K; Marcus R; de Vos J; Young AM; Tenant-Flowers M; Orkin C; Johnson M; Chilton D; Gribben JG; Bower M
J Clin Oncol; 2012 Nov; 30(33):4111-6. PubMed ID: 23045581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]